Addex Therapeutics Files 6-K, Incorporates Exhibits
Ticker: ADXN · Form: 6-K · Filed: Sep 30, 2024 · CIK: 1574232
Sentiment: neutral
Topics: sec-filing, 6-k, registration
TL;DR
Addex Therapeutics filed a 6-K, incorporating exhibits into its F-3 and S-8 filings.
AI Summary
Addex Therapeutics Ltd. filed a Form 6-K on September 30, 2024, to report information as a foreign private issuer. This filing incorporates by reference exhibits 99.1 and 99.2 into its existing registration statements on Form F-3 and Form S-8.
Why It Matters
This filing updates the SEC with information from Addex Therapeutics Ltd., potentially impacting investors' understanding of the company's ongoing disclosures and registration status.
Risk Assessment
Risk Level: low — This filing is a routine disclosure for a foreign private issuer and does not appear to contain significant new financial or operational information.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- 001-39179 (company) — SEC File Number
- 333-255089 (company) — Form F-3 Registration Number
- 333-255124 (company) — Form S-8 Registration Number
- 333-272515 (company) — Form S-8 Registration Number
FAQ
What is the purpose of this Form 6-K filing by Addex Therapeutics Ltd.?
The Form 6-K is a report of a foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report information that the company makes or is required to make public in its home country or to its security holders.
Which registration statements are updated by the incorporation of exhibits 99.1 and 99.2?
Exhibits 99.1 and 99.2 are incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) and the registration statements on Form S-8 (Registration No. 333-255124 and No. 333-272515).
What is the filing date of this Form 6-K?
The filing date is September 30, 2024.
What is the principal executive office address of Addex Therapeutics Ltd.?
The principal executive offices are located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Does Addex Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
Addex Therapeutics Ltd. indicates it files annual reports under Form 20-F.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-09-30 06:01:20
Filing Documents
- tm2425107d1_6k.htm (6-K) — 17KB
- tm2425107d1_ex99-1.htm (EX-99.1) — 1098KB
- tm2425107d1_ex99-2.htm (EX-99.2) — 198KB
- tm2425107d1_ex99-3.htm (EX-99.3) — 53KB
- 0001104659-24-103840.txt ( ) — 1367KB
RISK FACTORS
RISK FACTORS Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form 6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in our Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission on April 18, 2024 and updated in our prospectus (No.333-271611) amended on April 24, 2024. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described in our Annual Report and our other SEC filings. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd By: /s/ Tim Dyer Name: Tim Dyer Date: September 30, 2024 Title: Chief Executive Officer 3 EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 : Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.2 : Management's Discussion and Analysis of Financial Condition and Result of Operations Exhibit 99.3 : Press Release dated September 30, 2024 4